All news

CG Oncology jumps over 30% as bladder cancer therapy cuts recurrence risk by 68%

Reuters (via SRN News) · · AI-summarised by FinFlash

CG Oncology said its immunotherapy cretostimogene grenadenorepvec cut the risk of tumor recurrence by 68% in intermediate-risk non-muscle-invasive bladder cancer, meeting the main goal of a late-stage study of 367 patients. The drug was generally well tolerated. Shares rose more than 30% to $98 premarket. The company plans to file with the FDA before the end of March 2027 and will present more data in December.

So What?

A clear win for CG Oncology and a read-across for bladder cancer competitors; watch the regulatory filing timeline and December data.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.